RE:RE:RE:RE:RE:Approval in September
In my view the ITA approval is likely to only satisfy the penny day traders. The smart money won't let the sp get out of hand while the company is shopping a PP around. Don't expect them to throw Roger a life jacket when he negotiates PP prices.
The big question for many speculators becomes what will a report to the market consist of after treating 3 patients with a low dose of their drug and observing them for only 30 days? The company will no doubt try to hype up the results to the max but in reality apart from the market expectation that safety and tolerability protocols will be met from a super weak first time dose, what else can Roger really say on efficacy indicators that would sound credible to the cancer community at large at such an early stage? You don't declare efficacy or what some on this board would have us believe is a cure for cancer after exposing 3 patients to those kind of non taxing conditions? It's just not done. Even if Roger would want to proclaim something stronger to appease his shareholders, I can't see the scientific team putting their reputations on the line by agreeing to anything other then a general statement along the lines that the data looks promising. They may not have shareholders to contend with but as well known researchers in the cancer field they do have peer pressure that demands the keep to the highest standards.
In the end, nobody really knows for sure how the market will react as the trial inches along. The big test if you are long and not just speculating on bits of manufactured hocus pocus by the pumperoids will be at the trial's conclusion when the TLT researchers, the committee overseeing the trial and Health Canada will look over the data and come up with a joint statement. Even then there are no guarantees you'll be able to buy your dream Ferrari if we still have a junior market that seems to be always in a bad mood but you may have something more solid to bet on as they go into a phase 2 trial.